Learn How to Pronounce resmetirom
(Listen to the audio above for the stress and intonation)
The Expert's Take

Meaning and Context
Resmetirom is a first-in-class, orally administered thyroid hormone receptor-beta (THR-β) agonist specifically developed to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). Approved by the U.S. Food and Drug Administration (FDA) in March 2024 under the brand name Rezdiffra, it represents a landmark therapeutic breakthrough for a condition characterized by liver inflammation, fibrosis, and excessive fat accumulation, which had no previously approved pharmacologic treatments. By selectively activating THR-β receptors in the liver, resmetirom enhances metabolic function, leading to significant reductions in hepatic fat content, inflammation, and liver enzyme levels, thereby addressing a critical unmet need in hepatology and metabolic disease management. Its development and approval mark a pivotal shift from diagnosis and lifestyle management to targeted pharmacologic intervention for advanced MASH patients with moderate to advanced liver fibrosis.
Common Mistakes and Alternative Spellings
The standard and correct spelling is resmetirom. Common errors and variations often arise from phonetic misspellings or typographical mistakes. Frequent misspellings include "resmetiron," swapping the 'o' and 'r' at the end, and "resmertiom," transposing the 'e' and 'r'. Other variants such as "resmetiromm" (double 'm') or "resmetrium" (substituting 'um' for 'om') are also occasionally seen. It is important to note the precise "meti" sequence in the middle of the word. In professional and scientific literature, the term is uniformly spelled as resmetirom, and its brand name, Rezdiffra, follows its own distinct spelling conventions and should not be used interchangeably as a spelling variant for the drug's generic name.
Example Sentences
Following the landmark FDA approval, hepatologists can now prescribe resmetirom for eligible MASH patients with significant liver fibrosis.
Clinical trial data demonstrated that patients on a daily dose of resmetirom showed a statistically significant reduction in liver fat compared to the placebo group.
As a thyroid hormone receptor-beta agonist, the medication's mechanism of action is highly targeted to hepatic tissue, minimizing off-target effects.
The introduction of resmetirom into treatment guidelines has fundamentally altered the therapeutic landscape for metabolic liver disease.
While effective, clinicians monitor patients on resmetirom for potential side effects, such as mild gastrointestinal disturbances.
Ongoing post-marketing studies will further elucidate the long-term impact of resmetirom on liver-related outcomes and overall patient survival.
Sources and References
I researched the pronunciation of this drug name using its entry on Drugs.com and its page on Wikipedia. I listened to the audio available on Forvo. I also used YouGlish to find recent medical news reports, investor presentations, and scientific podcasts where the medication is discussed.
- https://en.wiktionary.org/wiki/resmetirom
- https://en.wikipedia.org/wiki/Resmetirom
- https://www.drugs.com/resmetirom.html
- https://www.drugs.com/monograph/resmetirom.html
- https://youglish.com/pronounce/resmetirom/english
Related Pronunciations
- How to pronounce Nutramigen
- How to pronounce adapelene
- How to pronounce Brinsupri
- How to pronounce olanzapine
- How to pronounce Maxipime